metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus placebo
	pembrolizumab alone
	KEYNOTE 054 (all population), 2018 N. Engl. J. Med. 2018; 378:1789-1801 JAMA Oncol 2020; : European Journal of Cancer 2019; 116:148-. J Clin Oncol 2020 Sep 18;JCO2002110. J Med Econ 2019 Oct;22(10):981-993. JAMA Oncol 2020; 6:519-527 Lancet Oncol 2021 Apr 12;S1470-2045(21)00065-6. Lancet Oncol 2021 Apr 12;S1470-2045(21)00081-4. NEJM Evidence NCT02362594	RCT	mML - NA - all population	pembrolizumab	placebo	patients with complete Resection of High-Risk Stage III Melanoma, stage IIIA, IIIB or IIIC melanoma with no in-transit metastases,	514 / 505	low	conclusif	demonstrated 43 % decrease in RFS/DFS (PE) suggested 47 % decrease in MFS suggested 44 % decrease in RFS (extension) suggested 41 % decrease in RFS (extension) more...
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
versus placebo
	pembrolizumab alone
	KEYNOTE 054 (PDL1>1%), 2018 N. Engl. J. Med. 2018; 378:1789-1801 JAMA Oncol 2020; : European Journal of Cancer 2019; 116:148-. J Clin Oncol 2020 Sep 18;JCO2002110. J Clin Oncol 2020 Nov 20;38(33):3925-3936. J Med Econ 2019 Oct;22(10):981-993. Lancet Oncol 2021 Apr 12;S1470-2045(21)00065-6. Lancet Oncol 2021 Apr 12;S1470-2045(21)00081-4. NCT02362594	RCT	mML - NA - PDL1 positive	pembrolizumab	placebo	patients with complete Resection of High-Risk Stage III Melanoma, stage IIIA, IIIB or IIIC melanoma with no in-transit metastases, with PDL1 positive status	428 / 425	low	conclusif	demonstrated 46 % decrease in RFS/DFS (PE) suggested 43 % decrease in RFS (extension) demonstrated 40 % decrease in DMFS (PE)